
一品红
ApicHope
股票代码
300723.SZ

☑

☑

☑

☑

ApicHope 300723.SZ 2002

—— 2017 11 20

218 97

26 2

93,227.05

GMP

GMP GMP GMP

KA

C 27

30%

2025 6 2025 16

5 16

2025 7 8

2025 10

20

2025 12 2025 2025

114 50 3,253 1,857

1,396

18 19 4

15 5 CAR-T 6 2

2026 1

2 7

2019

387 147

2025-2027

3 2025—2027 2027

2025 9

2025 86

30 10

15 374

2016 144

32 8

16

30

2019 13.3% 1.1%
60 μmol/L 1.4 17%
12% CKD
2019 1.83
2024 2.21 3.8% 2033 2.86 2024 2033
2.9%

2002

100



MDS 2025 2024

TOP100 2025 PDI ·

2025 TOP100 40 2025

TOP100 79

0-14

30

32 (2025 116

AR882

APH03621 18 76

AR882 2025 6 AR882

2025 EULAR

AR882

AR882 18 AEs

478 2025 10 AR882 2025

AR882

AR882 2024

FDA FTD ZDPZ20240007

2025 11 AR882 AR882

40

14 19 /

First-in-class

20,199.01

21.67%

8

125ml:2.5g 3350

4

11

AR882 APH03621 18

76

AR882 APH03621

18 AR882

URAT1

2025 EULAR

ApicHope

31

KA

——

GMP

93,227.05 -33,779.46 2025 12 31
404,223.93 2025

1 URAT1
AR882
2025 3 4 AR882
AR882 3 6
AR882 REDUCE 2
AR882 3 17 AR882
REDUCE 1 REDUCE 1 REDUCE 2 AR882
SUA 6 sUA
2025 6 13 AR882
URAT1
2025 EULAR
AR882
AR882 18 AEs
478 8 21 AR882
10 24 AR882 2025
AR882
11 13 AR882
AR882 AR882
AR882 AR882
680
Arthrosi 15.25% AR882
100%
AR882 100% Arthrosi
AR882 AR882

AR882

2026 2 Arthrosi 11,915.89 82,353.10

Degron Therapeutics

-

GlueXplorer®

10

Journal of Medicinal Chemistry

APH02174 IRAK4

PROTAC IRAK4

APH02174

APH02174

CDE FDA IND

MRGPRX2 AM-001

MRGPRX2 AM-001

G

GPCR GPCR-AI 2021 GPCR-DOCK

60% AphaFold2 2025 10 ·

CXG87 /

DPI

CXG87

2025 5 1 Clinical Pharmacology Therapeutics CPT

CXG87 / CXG87 Symbicort® Turbuhaler®

2025 10

SAP ERP WMS) WCS SRM DCS

2025 9

2025

24

2025 351 765.18

1.694% 2024

1,534,831 0.34% 134

SAP WMS

93,227.05 -33,779.46 2025

30 , 0~14 70%

8

2024

2025 2025 12

32 (2025 116

125ml:2.5g 3350 4

76

AR882 APH03621 18

11

AR882 2025

11 AR882 AR882

100% Arthrosi AR882

AR882

100%

45

36 90 2025

2026 2 1-8

15

KA

2025

A 10,000 20,000

70.00 / 2026 3 13 10,998.44 316.22

0.70%

2025

2026

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

			0 1					

2026 1 2026 5 15

2015

2026

“

”

2025 76 85% 4

BD Business Development MNC Multi National Company 2025

license-out 158 1,357 70

10

AI 28%

40% 8% 17% 7% AI

AI

/

2026

2026

GMP GSP

GMP

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

								01	

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

		○



☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑





☑

☑

☑

☑

☑

☑

☑

☑

☑

	01						

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑

☑